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Small cell lung cancer (SCLC) is a neuroendocrine
lung cancer characterized by fast growth, early
dissemination, and rapid resistance to chemo-
therapy. We identified a population of long-term
tumor-propagating cells (TPCs) in a mouse model of
SCLC. This population, marked by high levels of
EpCAMandCD24, is also prevalent in human primary
SCLC tumors. Murine SCLC TPCs are numerous and
highly proliferative but not intrinsically chemoresist-
ant, indicating that not all clinical features of
SCLC are linked to TPCs. SCLC TPCs possess a
distinct transcriptional profile compared to non-
TPCs, including elevated MYC activity. Genetic and
pharmacological inhibition of MYC in SCLC cells to
non-TPC levels inhibits long-term propagation but
not short-term growth. These studies identify a
highly tumorigenic population of SCLC cells inmouse
models, cell lines, and patient tumors and ameans to
target them in this most fatal form of lung cancer.INTRODUCTION
Small cell lung cancer (SCLC), which represents 15% of lung
cancers, is characterized by small cells with neuroendocrine fea-
tures (Wistuba and Gazdar, 2006). Close to 200,000 people die
from SCLC every year worldwide, and the 5-year survival rate
is a dismal 5%–10%. SCLC disseminates early and is usually de-
tected late when patients present with extensive metastases.
Patients often respond well initially to chemotherapy (usually a
combination of etoposide and a platinum-based agent), but
they almost invariably relapse with disease that is resistant to
their primary therapy and other agents. Despite numerous clin-644 Cell Reports 16, 644–656, July 19, 2016 ª 2016 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://ical trials, no new treatment has been approved in two decades
and SCLC remains the most lethal form of lung cancer (Pietanza
et al., 2015).
The cancer stem cell model assumes a hierarchical organiza-
tion in which a subset of tumor cells is responsible for sustaining
tumorigenesis and establishing the cellular heterogeneity of a
primary tumor (Beck and Blanpain, 2013; Clarke et al., 2006; Ma-
gee et al., 2012; Visvader and Lindeman, 2012). Not all tumors
may be organized in such a hierarchical manner (Meacham
and Morrison, 2013; Quintana et al., 2010). The aggressive and
highly metastatic nature of SCLC tumors suggests that SCLC
tumors may harbor highly tumorigenic cells. However, the study
of SCLC is challenging in patients because of the inherent com-
plex genetic and environmental diversity of these patients. SCLC
patients rarely undergo surgery, and primary human material is
scarce. Moreover, the establishment of SCLC cell lines and pa-
tient-derived xenografts can select for the growth of specific
populations of tumor cells (Daniel et al., 2009; Leong et al.,
2014), which may bias the analysis of cancer cell subpopula-
tions. In contrast, relevant mouse models allow for the analysis
of large number of independent primary tumors. The first mouse
model for SCLC was developed based on the observation that
human SCLCs are mutant for both the p53 and the RB tumor
suppressors (Meuwissen et al., 2003). The additional deletion
of the p130 gene (also known as Rbl2) enhances SCLC develop-
ment (Schaffer et al., 2010). Tumors that are triple knockout
(TKO) for Rb (also known as Rb1), p130, and p53 (also known
as Tp53) have histopathological features of human SCLC,
including an initial relative chemosensitivity followed by the
acquisition of chemoresistance (Gazdar et al., 2015; Jahchan
et al., 2013; Park et al., 2011).
Here we use mouse models and human SCLC cells to investi-
gate tumor heterogeneity in SCLC. Because cancer stem cells
may not possess the exact and full repertoire of normal tissue
stem cell properties, we instead use the term tumor-propagating
cells (TPCs). We define TPCs as cells that are highly tumorigeniccreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Mouse SCLC Tumors Contain a High Fraction of Tumor-Propagating Cells in Transplantation Assays
(A) Workflow to identify TPCs in a pre-clinical mouse model of SCLC (TKO, Rb/p53/p130 mutant).
(B) Representative flow cytometry analysis of TKO SCLC cells with markers of cell death (7AAD), lineage (CD45, CD31, and Ter119), CD24, CD44, and EpCAM
(n > 20).
(C) ELDA of lineage-negative (Lin, bulk tumor cells), CD24High CD44Low EpCAMHigh/Low cells sorted from TKO tumors and injected subcutaneously in NSGmice.
See also Figure S1.in transplantation assays and that can self-renew and differen-
tiate into the bulk tumor population. We found that SCLC TPCs
are highly abundant and are proliferative but not inherently che-
moresistant in a mousemodel. We also identified similar popula-
tions marked by high levels of the cell surface markers EpCAM
and CD24 and low levels of CD44 in primary human explant
models. Finally, we identified elevated MYC activity, in particular
L-MYC, as a key determinant of the ability of SCLC TPCs to
maintain the long-term growth of SCLC tumors.
RESULTS
SCLC Tumors Contain a High Fraction of TPCs
To investigate the presence of TPCs in primary Rb/p130/p53
TKO tumors, we injected serial dilutions of tumor cell suspen-
sions subcutaneously into Nod.Cg-PrkdcscidIL2rgtm1Wjl/SzJ
(NSG) mice (Figures 1A and 1B). In these assays, the calculated
frequency of tumor initiation was 1/128 (Figure 1C). This num-
ber is more than ten times higher than the number observed with
mouse models of lung adenocarcinoma (Zheng et al., 2013) and
is similar to that of highly aggressive breast cancer models
(Vaillant et al., 2008), suggesting that TPCs may be abundant
in murine SCLC tumors.
We next examined cell surface markers previously associated
with TPCs in a few SCLC cell lines or in other solid tumor types,
including CD133 (Jiang et al., 2009; Sarvi et al., 2014), CD90 (Sal-
cido et al., 2010;Wang et al., 2013), c-KIT (Micke et al., 2003; Ry-gaard et al., 1993), and hepatocyte growth factor receptor
(HGFR) (Rygaard et al., 1993). Transplantation trials with 500–
5,000 mouse tumor cells sorted for each of these markers inde-
pendently showed no trend in enrichment (or loss) of tumorigenic
potential (data not shown). In contrast, high levels of CD24 en-
riched for TPCs, and the transplantation ability of CD24High cells
was further increased by selecting for CD44Low and EpCAMHigh
cells (Figures 1B, 1C, S1A, and S1B). Using a tumor-specific
GFP reporter, we found that both TPC and non-TPC populations
identified by these three markers are tumor cells (Figures S1C
and S1D). These populations were also found in individually
dissected tumors (Figure S1E) and in an Rb/p53 mutant primary
tumor (Figure S1F). Overall, CD24High CD44Low EpCAMHigh
SCLC cells represent 50% of live tumor cells (Figure S1G).
Thus, TKO tumors harbor a high number of SCLC cells with the
ability to transplant tumors, and the combination of CD24High,
CD44Low, and EpCAMHigh identifies cells that transplant 100
times more efficiently than other SCLC cell populations. We
found that SCLC cells seed tumors in the liver but not the lungs
following intravenous injection and do not reliably form lung
tumors following intratracheal instillation, preventing us from
investigating TPCs in an orthotopic model (data not shown).
SCLC patients rarely undergo surgery, andwewere not able to
perform transplantation assays with fresh human specimens.
Nevertheless, EPCAM and CD24 mRNA levels are high and
CD44 expression is low in human SCLC cell lines and primary
bulk tumors (Figure S2A). Circulating tumor cells (CTCs) fromCell Reports 16, 644–656, July 19, 2016 645
Figure 2. Xenografts Derived from Human
SCLC CTCs Harbor a High Frequency of
TPCs and High Numbers of CD24High
CD44Low EpCAMHigh Cells
(A) Workflow to generate xenografts (CDXs)
derived from human SCLC CTCs.
(B) Expression (reads per kilobase of transcript
per million mapped reads [RPKM], from RNA
sequencing) of two genes expressed at high levels
in SCLC (ASCL1 and SYP) compared to the TPC
markers EPCAM, CD24, and CD44 (n = 3 CDXs).
Negative controls: FOXN1, thymic and skin
epithelium; MYBPC3, heart. Levels of the three
MYC genes are also shown.
(C) Immunostaining for EpCAM and CD44 (brown
signal) on CDX models. Lymphoma SUDHL8 cells
were used as a negative control for EpCAM (left
inset), and H196 lung cancer cells were used as a
positive control for CD44 (right inset). Counterstain
was hematoxylin. Scale bars, 100 mm.
(D) ELDA of cells from the CDX2, CDX3, and CDX4
models. The data for CDX2 and CDX4 are not
statistically different, but the lower frequency for
CDX3 is (p values of 1.1231007 for the CDX2
comparison and 3.5131005 for CDX4).
See also Figure S2.SCLC patients form CDX (CTC-derived explant) tumors with a
take rate of50%under the skin of NSGmice (Figure 2A) (Hodg-
kinson et al., 2014; Krebs et al., 2014). Although human SCLC
CTCs are not enriched for EpCAM expression before assaying
their transplantation ability and EpCAM CTCs can be found in
the blood of SCLC patients (Chudziak et al., 2016), CDX tumors
express high mRNA levels of CD24 and EpCAM and low levels
of CD44 (Figure 2B). Fluorescence-activated cell sorting
(FACS) analysis on three CDX models showed that an average
of 41% of human SCLC cells was CD24High CD44Low EpCAMHigh
(42%, 27%, and 55% for CDX2, CDX3, and CDX4, respectively)
(Figure S2C). These observations were confirmed by immuno-
staining for EpCAM and CD44 on tumor sections (Figure 2C).
The frequency of TPCs using single cells dissociated from CDX
models was similar to that seen with mouse TKO TPCs (compare
Figure 2D to Figure 1C). Cells in patient-derived xenografts
(PDXs) (e.g., PDX model LU95) were nearly exclusively CD24High
CD44Low EpCAMHigh, and EpCAM+ cells were able to confer
tumorigenicity (Figure S2D) (Saunders et al., 2015). High
levels of EpCAM expression (but not CD24; data not shown) in
early-stage tumors (George et al., 2015) correlated with
decreased survival in SCLC patients (Figure S2E), suggesting
that a high level of EpCAM is associated with more aggressive
tumors.
CD24High CD44Low EpCAMHigh Mouse SCLC Cells Give
Rise to TPCs and Non-TPCs and Can Be Serially
Transplanted
We next tested the long-term propagation ability of CD24High
CD44Low EpCAMHigh SCLC cells, focusing on TKO tumors
because of the availability of numerous primary tumors (Fig-
ure 3A). TKO CD24High CD44Low EpCAMHigh SCLC cells could
generate new tumors at a similar frequency each time they
were passaged (Figures 3A and S3A). The passaged tumors646 Cell Reports 16, 644–656, July 19, 2016retained histopathological features of SCLC tumors, including
expression of the neuroendocrine markers ubiquitin-C-terminal
hydrolase 1 (Uchl1, also known as PGP9.5) and Ascl1 (Figures
3B and S3B). In addition, tumors initiated by CD24High CD44Low
EpCAMHigh cells gave rise to all subpopulations of cells found in
primary tumors (Figure 3C). CD24High CD44Low EpCAMHigh cells
were not quiescent and had similar proliferative rates compared
to CD24High CD44Low EpCAMLow cells or to all non-TPCs popu-
lations combined (Figures 3D, 3E, and S3C). Thus, actively
cycling CD24High CD44Low EpCAMHigh SCLC cells self-renew
and are enriched for the ability to propagate all tumor popula-
tions in this mouse model.
CD24High CD44Low EpCAMHigh TPCs Are Not Inherently
Chemoresistant
Cancer stem cells have been associated with chemoresistance
and tumor relapse (Shafee et al., 2008; Visvader and Lindeman,
2012; Zheng et al., 2013). To investigate how TPCs responded to
chemotherapy compared to non-TPCs, TKO mice carrying an
inducible luciferase reporter allele (Rosa26lox-Stop-lox-Luciferase)
were monitored for tumor development in response to chemo-
therapy. At the end of each experiment, the relative frequency
of TPCs was assessed by flow cytometry. Acute treatment
with high doses of cisplatin and etoposide (Figure 4A) led to a
significant induction of apoptosis in tumors, as monitored by
cleaved caspase-3 (CC3) immunostaining (Figures 4B and
S4A), but there was no difference in the frequency of cells
with TPC markers (CD24High CD44Low EpCAMHigh) versus non-
TPCs (CD24High CD44Low EpCAMLow, CD24Low, and CD24High
CD44High) in this assay (Figures 4C and S4B). Analysis of TPCs
and non-TPCs following 6 days of recovery after 3 days of acute
treatment in a similar setting showed no differences in the rela-
tive percentages for these two populations; in addition, we
observed no differences in the proliferative rate of TPCs from
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Figure 3. Serial Transplantation Reveals
a Stable TPC Phenotype in the Murine
CD24High CD44Low EpCAMHigh SCLC Cell
Population
(A) Serial transplantation assays (passages P1, P2,
and P3) of sorted lineage-negative cells (Lin:
CD45, CD31, and Ter119) and TPCs (CD24High
CD44Low EpCAMHigh) from TKO tumors (P0). The
estimated frequency of tumor formation is shown
in red. Tumors from two TKO mice were passaged
to P3, and analysis was done on a minimum of two
allografts per passage for each.
(B) Representative sections from the Lin P1, TPC
P1, TPC P2, and TPC P3 allografts counterstained
with H&E or immunostained for the neuroendo-
crine marker Uchl1. Scale bars, 50 mm.
(C) Representative FACS plots of TPCs (red boxes)
and non-TPCs (black boxes) from LinP1, TPCP1,
TPC P2, and TPC P3 allografts (n > 2).
(D) Representative FACS histograms of TPCs and
non-TPCs (CD24High CD44Low EpCAMLow) tumor
subpopulations labeled with the DNA replication
marker EdU.
(E) Bar chart showing the frequency of EdU+
cycling cells in TPCs and non-TPCs (CD24High
CD44Low EpCAMLow) tumor subpopulations
from three different Rb/p53/p130 mutant mice.
CD24High CD44High and CD24Low populations also
showed non-significant differences in EdU incor-
poration (data not shown). NS, not significant; error
bars represent mean ± SEM (n = 3 mice); p values
are from a paired t test (p = 0.1151).
See also Figure S3 for information related to the
frequency of the TPC population.saline-treatedmice and chemotherapy-treatedmice, suggesting
that TPC populations do not rebound after treatment under these
conditions (data not shown).
The cisplatin-etoposide combination therapy was toxic to
these tumor-bearing mice when applied for longer periods, so
we used cisplatin only (5 mg/kg) or control saline weekly for
longer experiments (Figure 4D). Luciferase imaging confirmed
that cisplatin inhibited overall tumor growth (Figure 4E). How-Cever, there was again no significant rela-
tive enrichment in CD24High CD44Low
EpCAMHigh populations versus non-
TPCs in this assay (Figures 4F and S4C).
To examine the response of single tumors
to treatment, we grew isolated TKO tu-
mors subcutaneously as allografts into
NSG mice (Figure 4G). Cisplatin-treated
allografts were significantly smaller than
saline-treated tumors after 3 weeks of
treatment, as expected (Figure 4H), but
the relative frequency of CD24High
CD44Low EpCAMHigh cells remained the
same as in the control group (Figures 4I
and S4D). We recently described TKO
mice carrying tumors treated weekly
with cisplatin or saline until chemoresist-ant tumors were selected (Figure 4J) (Jahchan et al., 2013).
The analysis of these chemoresistant tumors showed again no
significant increase in the relative number of TPC cells versus
non-TPCs (Figures 4K and S4E).
These experiments do not address how chemotherapy may
affect the long-term propagation ability of CD24High CD44Low
EpCAMHigh cells, but they do show that these cells are neither
intrinsically resistant to chemotherapeutic agents used inell Reports 16, 644–656, July 19, 2016 647
Figure 4. The Murine CD24High CD44Low
EpCAMHigh TPC Population Is Not Inher-
ently Chemoresistant
(A) Strategy used for the acute treatment of Rb/
p53/p130 TKO mutant mice with saline and high
doses of cisplatin (7.5 mg/kg) and etoposide
(15 mg/kg) for 4 days.
(B) Analysis of CC3-positive apoptotic cells on
sections from TKO tumors treated acutely with
saline or cisplatin and etoposide. n = 3 mice;
p = 0.0442.
(C) Relative frequency of CD24High CD44Low
EpCAMHigh cells from treated TKO mice. n = 3
mice; p = 0.8490.
(D) Strategy used for the treatment of Rb/p53/
p130;Rosa26lox-Stop-lox-Luciferase mice with saline
and cisplatin (5 mg/kg) once a week for 3 weeks.
(E) Fold change of the tumor volume measured by
luciferase activity in saline- and cisplatin-treated
mice. n = 3 mice; p = 0.0455.
(F) Relative frequency of TPCs (CD24High
CD44Low EpCAMHigh) in treated mice. n = 3 mice;
p = 0.2674.
(G) Strategy used for the treatment of passage
P2 allografts transplanted into NSG mice
from single TKO tumors; pairs were treated with
saline or cisplatin (5 mg/kg) once a week for
3 weeks.
(H) Tumor mass from saline-treated allografts
(n = 8 tumors) and cisplatin-treated allografts (n = 5
tumors). p = 0.0431.
(I) Relative frequency of TPCs (CD24High CD44Low
EpCAMHigh) in treated allografts. n = 3 mice;
p = 0.1191.
(J) Strategy used for the treatment of Rb/p53/
p130;Rosa26lox-Stop-lox-Luciferase mice developing
endogenous SCLC tumors and treated with saline
or cisplatin (3 mg/kg) weekly to generate chemonaive and chemoresistant tumors (from Jahchan et al., 2013).
(K) Relative frequency of TPCs (CD24High CD44Low EpCAMHigh) in treated mice. n = 3 saline-treated mice and 3 cisplatin-treated mice; p = 0.2172.
NS, not significant; error bars represent mean ± SEM; p values are from two-tailed unpaired Student’s t tests. See also Figure S4.SCLC patients nor enriched after chemoresistant tumors arise.
The CDX3 and CDX4 models represent two extremes of chemo-
therapy response (Hodgkinson et al., 2014; C.D., unpublished
data), yet in the limiting dilution studies, CDX4 tumors (the least
chemosensitive) had a lower frequency of tumor-initiating cells
and fewer CD24High CD44Low EpCAMHigh cells compared to
CDX3 tumors (most chemosensitive) (Figures 2E and 2F), uncou-
pling drug response from tumorigenicity. Thus, markers associ-
ated with TPCs may not be relevant biomarkers to predict
relapse, and the mechanisms of chemoresistance remain poorly
understood in this cancer type.
Mouse SCLC TPCs Retain Their Neuroendocrine
Differentiation
To identify candidate regulators of mouse SCLC TPCs and their
long-term growth properties, we compared the transcriptional
profiles of CD24High CD44Low EpCAMHigh cells and non-TPCs
(Figure 5A). Unsupervised clustering separated the TPC and
non-TPC groups (Figure S5A). Supervised clustering of genes
differentially expressed at least 1.5-fold between the two popu-
lations identified 698 genes upregulated in TPCs and 1,919 up-
regulated in non-TPCs (Figure 5B; Table S1). Even at this low648 Cell Reports 16, 644–656, July 19, 2016stringency for statistical cutoff, gene set enrichment analysis
(GSEA) for Gene Ontology Consortium terms yielded no signifi-
cantly enriched terms for TPCs, but the non-TPCs were enriched
for terms related to extracellular matrix, wound remodeling, and
chemokine/cytokine activity (Table S2). The analysis of onco-
genic signatures revealed that the TPCs genes were enriched
in a neuronal/neuroendocrine signature (CAHOY_NEURONAL)
(Table S3).
Using a low-stringency approach (see Experimental Proce-
dures), 154 genes were identified as specifically upregulated in
TPCs (Table S4). A qRT-PCR analysis on an independent set
of tumors confirmed the general upregulation of a few of these
genes in TPCs (Figure S5B). Ascl1 expression was increased in
TPCs compared to non-TPCs (Figure S5B; Table S4). ASCL1 is
a driver of neuroendocrine differentiation (Ito et al., 2000) and
an oncogene in SCLC whose activity may promote the tumor-
initiating capacity of SCLC cells (Augustyn et al., 2014; Jiang
et al., 2009). We also found expression of the neuroendocrine
marker CD56 (neural cell adhesion molecule [NCAM]) on the sur-
face of TPCs (Figure S5C). Thus, the long-term self-renewal of
mouse SCLC TPC populations is compatible with differentiated
epithelial features.
Figure 5. SCLC TPCs Retain Their Neuroendocrine Differentiation and Have Elevated Mycl1 Levels
(A) Representative FACS plots to isolate TPCs (red gates, CD24High CD44Low EpCAMHigh) and non-TPCs (black gates, CD24Low , CD24High CD44High , and
CD24High CD44Low EpCAMLow) populations in TKO tumors (nR 3).
(B) Heatmap of the microarray analysis comparing TPCs and non-TPCs sorted from three TKO mice. Yellow and blue indicate high and low expression,
respectively. The values of the scale bar represent the median-centered log2 fold change of each gene. Hierarchical clustering was performed on genes whose
expression is at least 1.5-fold different between the two groups.
(C) Top 10 overrepresented transcription factors in the TPC population (based on the total count of significantly enriched gene sets).
(D) qRT-PCR analysis ofMycl1mRNA levels in TPCs relative to non-TPCs (set to 1) from three TKOmice and one TKO passage P1 allograft.Arpp0was used as an
internal control to compare the different tumors. n = 4 samples; p = 0.0323.
(E) qRT-PCR analysis of Mycl1 mRNA levels in mouse Kp3 SCLC cells with small hairpin RNA knockdown using three hairpins (sh6, sh7, and sh8). Arpp0 and
B-actin were used as internal controls, and data were plotted relative to the small hairpin-scrambled vector control (shscr). n = 2 independent experiments;
p = 0.0142 for sh7.
(legend continued on next page)
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Elevated MYC Activity in SCLC TPCs Drives the
Clonogenic Ability of SCLC Cells
We performed Enrichr analysis to identify transcriptional regula-
tors of the 154 genes with elevated expression in TPCs. MYC
was one of the top 10 overrepresented terms when counting the
significantly enriched gene sets fromall databases in this analysis
(Figures 5C and S5D). The MYC family of transcription factors
(c-MYC, L-MYC, and N-MYC) is thought to be oncogenic in
SCLC (Huijbers et al., 2014; Teicher, 2014; Wistuba et al., 2001),
and most human and mouse SCLC tumors express high levels
of MYC factors (Figures 2B, S2A, and S2B). Mycl1 is the most
frequently amplified Myc family gene in mouse SCLC tumors
(Calbo´ et al., 2005; McFadden et al., 2014; Peifer et al., 2012).
Expression ofMycl1was specifically elevated in TPCs compared
to non-TPCs (Table S1), including in an independent set ofmouse
tumor samples (Figure 5D). MYCL1 levels were also higher in
CD24High CD44Low EpCAMHigh cells compared to CD24High
CD44Low EpCAMLow cells in two CDX models (Figure S5E).
To test for a possible functional role ofMycl1 elevated levels in
mouse TPCs, we knocked down Mycl1 in murine Rb/p53 Kp3
cells, which are nearly entirely composed of CD24High CD44Low
EpCAMHigh cells (possibly by a selection process of tumorigenic
cells upon passaging or simply illustrating the heterogeneity of
SCLC tumors) (Figure S5F). Three independent hairpins reduced
L-Myc levels 2- to 5-fold (Figures 5E and 5F) but had little to no
effect on the growth of the tumor cells (Figure 5G). In contrast,
the three hairpins strongly inhibited colony formation, an
in vitro assay measuring the tumorigenic ability of single cells
(Figure 5H). In murine Rb/p53 mutant Kp1 cells, in which the
CD24High CD44Low EpCAMHigh population represent less than
half of the cells (data not shown), the sh6 hairpin knocked
down Mycl1 3-fold and had only modest inhibitory effects on
growth, but it led to a significant decrease in the ability to form
colonies (Figures S5G–S5I). CD24High CD44Low EpCAMHigh
Kp1 cells formed more colonies than their CD24High CD44Low
EpCAMLow counterparts, and Mycl1 knockdown decreased the
number of cells with TPC markers (Figures S5J and S5K).
Decreased levels of Mycl1 significantly reduced the ability of
Kp1 cells to form new tumors in the flanks of NSG mice (Fig-
ure 5I). Together, these experiments show that decreasing
L-Myc levels inhibits the potential for long-term growth in mouse
SCLC cell lines.
JQ1 Treatment Decreases the Frequency of Mouse
SCLC TPCs and Inhibits the Tumorigenic Potential of
These Cells
Inhibitors of bromodomain and extra-terminal (BET) proteins can
target genes highly expressed in tumors, including MYC tran-(F) Representative L-Myc immunoblotting from Kp3 cells infected with a small hair
sh8). Hsp90 was used as a loading control. Quantification of the bands for L-My
(G) Cell growth assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromi
normalized to day 0. n = 4 independent biological replicas with three technical
comparisons are not significantly different.
(H) Average of the number of colonies formed after single-cell sorting of Kp3 ce
experiments with three technical replicas each. p = 0.0402 for sh6, p = 0.0017 fo
(I) ELDA of shscr, sh6, sh7, and sh8 (Mycl1 knockdown) in mouse Kp1 SCLC cells
in vivo.
Error bars represent mean ± SEM; p values are from two-tailed paired Student’s
650 Cell Reports 16, 644–656, July 19, 2016scription factors in SCLC and other tumors (Bauer et al., 2012;
Christensen et al., 2014; Delmore et al., 2011; Filippakopoulos
et al., 2010; Love´n et al., 2013; Puissant et al., 2013; Zuber
et al., 2011). Treatment of Kp3 cells with escalating doses of
the JQ1 inhibitor (Delmore et al., 2011) did not significantly affect
the growth of these cell cultures at the lower concentrations
tested (Figures 6A and S6A). In contrast, continuous JQ1 treat-
ment strongly blocked the ability of single cells to form colonies
at these lower concentrations (Figure 6B). Similar results were
obtained for murine Kp1 cells (Figures S6B–S6D) and for human
H69 cells (Figures S6F and S6G). The ability of various dilutions
of mouse Kp1 cells to form tumors in NSGmice was significantly
inhibited by JQ1 treatment at a relatively low dose (25 mg/kg
daily from the day of injection, compared to 50–100 mg/kg in
studies by Bolden et al., 2014; Delmore et al., 2011; and Shima-
mura et al., 2013) (Figure 6D). The tumors that ended up growing
were smaller than control tumors, suggesting a dual effect of JQ1
on cancer re-initiation and long-term growth (Figures S6J and
S6K). Pre-treatment with JQ1 for 5 days was sufficient to signif-
icantly decrease the frequency of CD24High CD44Low EpCAMHigh
cells (Figure 6E), which correlated with a decreased ability to
form colonies (Figure 6F) and tumors (Figure 6G). These experi-
ments suggest that a relatively low dose of JQ1 perturbs
transcriptional networks in SCLC cells that are critical for the
self-renewal and the long-term growth of these tumor cells.
In all these experiments, JQ1 treatment reduced the expres-
sion of Myc family genes, especially Mycl1 (Figure 6C; Figures
S6E, S6H, and S6I). However, JQ1 has many more targets in
cells than this gene family (Christensen et al., 2014; Lockwood
et al., 2012; Tang et al., 2014). To determine whether the inhibi-
tion of the clonogenicity of SCLC cells by JQ1 was at least partly
mediated by its inhibitory effect on Myc genes, we overex-
pressed mouse L-Myc from retroviral constructs whose pro-
moter may be less affected by JQ1 than the genomic regulatory
regions controlling the expression of endogenous genes. A 1.5-
to 3-fold induction of L-Myc could partly rescue the effects of
JQ1 treatment in a colony-formation assay in Kp3 cells (Figures
6H and 6I); a similar partial rescue was observed in Kp1 cells
using a different viral vector (Figures S6L and S6M). The mecha-
nisms by which JQ1 treatment affects the biology of SCLC TPCs
are likely complex but may partly be explained by the downregu-
lation of MYC activity.
While JQ1 treatment is clearly not equivalent to MYC inhibi-
tion, treatment with this small molecule provides a way to deter-
mine the consequences of a loss of long-term growth potential in
SCLC TPCs in vivo. To test this possibility, we first repeated
limited dilution transplantation assays of TPCs using mouse pri-
mary cells directly isolated from TKO tumors (Figure 7A). Thesepin-control vector (shGFP) and three small hairpin-Mycl1 vectors (sh6, sh7, and
c is shown below the blot.
de [MTT]) in Kp3 cells at different days uponMycl1 knockdown. Fold growth is
replicas each. p = 0.016 at day 4 and p = 0.0416 at day 6 for sh8; all other
lls into 96-well plates. n = 3 (for sh6) and n = 4 (for sh7 and sh8) independent
r sh7, and p = 0.0079 for sh8.
injected at different dilutions into NSG recipient mice to assess tumor formation
t tests. See also Figure S5.
Figure 6. LoweringMycl1 Levels in Murine SCLC Cells with JQ1 Decreases the Frequency of TPCs and Inhibits the Tumorigenic Potential of
These Cells
(A) MTT viability assay for mouse Kp1 SCLC cells after 48 hr of treatment with increasing doses of JQ1. n = 3 independent experiments; p values are for drug-
treated cells versus control cells (p = 0.0222 for 100 nM JQ1).
(B) Average of the number of colonies formed after single-cell sorting of Kp1 cells into 96-well plates. n = 9 for 100 nM JQ1 and n = 7 for 250 nM JQ1; independent
experiments with three technical replicas each. p = 0.0003 for 100 nM JQ1 and p = 0.0019 for 250 nM JQ1.
(C) qRT-PCR analysis of Mycl1, Myc, and Mycn mRNA levels in mouse Kp1 SCLC cells treated with increasing doses of JQ1 for 24 hr. Arpp0 was used as an
internal control, and the numbers were plotted relative to the DMSO-treated Kp1 cells. n = 6 independent experiments for 100 nM JQ1 and n = 4 independent
experiments for 250 nM JQ1. p = 0.0010 for Mycl1 and p = 0.0464 for Mycn for 100 nM JQ1; p = 0.0061 for Mycl1 and p = 0.0450 for Mycn for 250 nM JQ1.
(D) ELDA of Kp1 cells injected at different dilutions into NSG recipientmice to assess the frequency of tumor formation in vivowhen treatedwith vehicle alone (Ctrl)
or with JQ1 at 25 mg/kg, starting at day 0 of transplantation and continuing for 2 weeks.
(E) Relative frequency of TPCs (CD24High CD44Low EpCAMHigh) in Kp1 cells treated with DMSO or with 100 and 250 nM JQ1 for 5 days. n = 5 independent
experiments. p = 0.0230 for 100 nM JQ1 and p < 0.0001 for 250 nM JQ1.
(F) Average number of colonies formed after single-cell sorting into 96 well plates of pre-treated Kp1 cells with DMSO, 100 nM JQ1 (pre-JQ100), and 250 nM JQ1
(pre-JQ250) for 5 days. n = 2 independent experiments with three technical replicas each. p = 0.0043 for pre-JQ250.
(G) ELDA of pre-treated Kp1 cells with DMSO and with 100 and 250 nM JQ1 (JQ1 pre-treated) for 5 days, injected at different dilutions into NSG recipient mice to
assess the frequency of tumor formation in vivo.
(H) qRT-PCR analysis ofMycl1mRNA levels in Kp1 cells stably infected with the pCDH-puro-L-Myc vector relative to uninfected Kp1 cells (Ctrl) (set to 1).Gapdh
and Arpp0 were averaged and used as internal controls. n = 2 repeats; p = 0.0063.
(I) Number of colonies from a single-cell sort of Kp1 cells stably infected with pCDH-puro-L-Myc and control uninfected Kp1 cells in media containing DMSO,
100 nM JQ1, and 250 nM JQ1. n = 3 independent experiments. Statistical significance was determined among all groups. p = 0.046 and p = 0.013 for the effects of
100 and 250 mM JQ1, respectively; p = 0.021 for the effects of JQ1 in L-Myc-expressing cells at both 100 and 250 mM; and p = 0.0015 for the rescue effects of
L-Myc on cells treated with 100 mM JQ1. The effects of L-Myc on control cells are NS.
NA, not applicable; NS, not significant; error bars represent mean ± SEM; p values are from two-tailed paired Student’s t tests. See also Figure S6.
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Figure 7. JQ1 Treatment Decreases the Frequency of TPCs and Inhibits Tumorigenesis in Murine Models
(A) Strategy used for sorting TPCs from TKO tumors and injecting them into recipient NSG mice treated with 25 mg/kg of JQ1 for the first 2 weeks.
(B) ELDA of the sorted TPCs in groups treated with the vehicle (control, Ctrl) or JQ1 was performed at the end of the experiment to assess the frequency of tumor
formation in vivo.
(C) Representative images of the passage P1 allografts from the sorted TPCs injected in recipient NSG mice, with the number of cells indicated and treated with
Ctrl or 25 mg/kg of JQ1 for the first 2 weeks.
(D) Strategy used for the treatment of TKO mice 5.5 months after Adeno-Cre instillation with 25 mg/kg of JQ1.
(E) Representative FACS plots of CD24High CD44Low EpCAMHigh and CD24High CD44Low EpCAMLow from tumors isolated from the Ctrl- and JQ1-treated Rb/p53/
p130 mutant mice 1 month following treatment (n = 4).
(F) Frequency of TPCs (CD24High CD44Low EpCAMHigh) in Ctrl- and JQ1-treatedmice. Error bars represent mean ±SEM (n = 4 pairs); p values are from a two-tailed
paired Student’s t test (p = 0.0151).
(G) Survival curve generated from the Rb/p53/p130 TKO mutant mice treated daily with intraperitoneal injections of vehicle (Ctrl) and 25 mg/kg of JQ1 starting
5.5 months after Adeno-Cre instillation (day 0 of treatment); median survival is 20.50 days for the vehicle-treated mice and 37 days for the JQ1-treated mutant
mice. n = 12 vehicle-treated mice and n = 12 JQ1-treated mice; p values are from a Mantel-Cox test (p = 0.0043).
See also Figure S7.assays showed a significant reduction in the number and the
size of tumors growing in recipient mice after treatment with
JQ1 compared to controls (Figures 7B and 7C), indicating that
JQ1 treatment inhibits the tumor re-initiation ability of SCLC
TPCs, as well as their long-term growth. Treatment of TKO;
Rosa26lox-Stop-lox-Luciferase mice after 5.5 months of adenovirus-
Cre recombinase (Adeno-Cre) infection with daily injections of
JQ1 at 25 mg/kg (Figure 7D) decreased the frequency of the
CD24High CD44Low EpCAMHigh population (Figures 7E and 7F).
At that time point, treatment significantly reduced the levels of
Myc family genes, especially Mycl1 (Figure S7A), but did not
affect the general histology of the tumors (Figure S7B). This
treatment led to a significant increase in survival compared to
the control group (Figure 7G), indicating that a relatively low
dose of JQ1 as a single agent can have therapeutic effects
in SCLC.652 Cell Reports 16, 644–656, July 19, 2016DISCUSSION
SCLC is the most fatal form of lung cancer. Here we found that
mouse primary SCLC tumors include a significant fraction of
long-term SCLC TPCs and uncovered molecular features of
these TPCs that may explain the aggressive nature of these
tumors and may provide new therapeutic options for SCLC
patients.
Intratumoral Heterogeneity in SCLC and Significant
Numbers of TPCs
Little is known about the subpopulations of tumor cells that
may exist within SCLC tumors and whether these subpopula-
tions are related to genetic or epigenetic changes (Calbo´ et al.,
2005; Semenova et al., 2015). We found that CD24High CD44Low
EpCAMHigh cells constitute around half of the cells in primary
murine SCLC tumors. The high number of TPCs is concordant
with the high frequency of tumor formation from CTCs directly
obtained from patients (Hodgkinson et al., 2014) and from pa-
tient-derived xenografts (PDX models) (Saunders et al., 2015).
While we cannot exclude that a subpopulation of cells exists
within CD24High CD44Low EpCAMHigh TPCs that may be even
more potent in its transplantation ability (and possibly more
quiescent and/or more chemoresistant), our current studies
point to a model in which cancer stem cells comprise a large
fraction of SCLC tumors and are actively cycling.
A small subset of mouse CD44High SCLC tumor cells ex-
presses lower levels of neuroendocrine markers and can pro-
mote the metastasis of neuroendocrine tumor cells (Calbo
et al., 2011; Kwon et al., 2015). These cells are present in the
non-TPC subpopulations, but our FACS analyses indicate that
other non-neuroendocrine tumor cells (defined by low or no
CD56 staining) are also present in this non-TPC subgroup
(data not shown). The functional interactions between TPCs
and various subtypes of non-TPCs may be critical in how
SCLC tumors grow, spread, and respond to treatment. How-
ever, the identities of the various subpopulations within the
non-TPC group and the exact roles they may have in SCLC
initiation, progression, and maintenance remain largely un-
known. Better knowledge of these subpopulations may be
critical to better understanding of tumor evolution and response
to treatment.
Cell Surface Markers for SCLC TPCs
We found that the number of CellSearch-enumerated, EpCAM+
CTCs was an independent prognostic biomarker for patient
overall survival using a cutoff of 50 CTCs per 7.5 ml of blood
(Hou et al., 2012). Moreover, in the 47 attempts in which we failed
to generate a CDX model from a SCLC patient’s blood sample,
34 of the 47 samples (72%) had an EpCAM+ CTC count below
this cutoff, whereas all 15 blood samples from patients for
whom a CDX model was successfully derived had a EpCAM+
CTC count > 50 (range 160 to >7,000). Direct comparison of
CellSearch, EpCAM+ CTC enumeration with a marker of inde-
pendent CTC enrichment based on cell size and deformability
suggests that EpCAM SCLCCTCs also exist andmay be abun-
dant (data not shown). However, overall, these human CTC data
strongly suggest that the EpCAM+ CTC subpopulation has tu-
mor-initiating capacity. These observations do not exclude that
additional markers exist that would further enrich for cells with
even higher transplantation ability. Thus far, our experiments
show no significant differences in the transplantation ability of
CD24High CD44Low EpCAMHigh cells that are CD90+ compared
toCD90 (frequencies of 1/320 versus 526, respectively, in these
specific experiments). CD24High CD44Low EpCAMHigh c-Kit+ and
CD24High CD44Low EpCAMHigh c-Kit have similar calculated
transplantation frequencies (1/102 versus 1/130, respectively,
in these specific experiments). Other markers may be tested in
the future in mouse and human models.
Rapid Emergence of Chemoresistant SCLC Is Not
Explained by the TPC Model
The highly proliferative nature of TPCs in SCLC and their abun-
dance may explain, at least partly, why these tumors are initiallyresponsive to chemotherapy (Pietanza et al., 2015; Semenova
et al., 2015). However, the mechanisms underlying the rapid
relapse of chemoresistant tumors remain unexplained and do
not seem to be connected to the intrinsic biology of TPCs, which
indicates that the frequency of TPCs would not be a good
biomarker for the growth of chemoresistant disease in patients
(also seen with a PDX model in Saunders et al., 2015). The least
chemosensitive CDX model (CDX4) has a lower frequency of
TPCs; this suggests that specific subpopulations of non-TPCs
may be more chemoresistant and might serve as protective
niches for TPCs (Hartmann et al., 2005; Pardo et al., 2006). We
did not observe a relative increase in CD44High cells (Calbo
et al., 2011) after chemotherapy treatment in our mouse models
(data not shown). Similarly, while CD133 expression has been
correlated with chemoresistance in SCLC cell lines (Kubo
et al., 2013; Sarvi et al., 2014), we did not observe an induction
of this marker in mouse chemoresistant tumors (data not shown).
Thus, the existence of a possible chemoresistant reservoir in
SCLC remains to be ascertained.
Molecular Mechanisms Underlying the Differences
between TPCs and Non-TPCs
Our gene expression studies indicate that non-TPCs are less
neuroendocrine than TPCs, but we do not yet fully understand
why non-TPCs are less tumorigenic than TPCs. TPCs express
high levels of neuroendocrine differentiation compared to non-
TPCs, including Ascl1, a key oncogenic factor in SCLC (Augus-
tyn et al., 2014; Jiang et al., 2009). Accordingly, treatment with a
drug-conjugated antibody against DLL3, a transcriptional target
of ASCL1 (Nelson et al., 2009), was shown to inhibit the trans-
plantation ability in human SCLC PDX models (Saunders et al.,
2015). We focused on MYC based on its known oncogenic role
in SCLC (Alves et al., 2014; Calbo´ et al., 2005; George et al.,
2015; Huijbers et al., 2014; Romero et al., 2014). Emerging evi-
dence from in vitro studies in glioblastoma (Wang et al., 2008)
and pancreatic cancer (Sancho et al., 2015) suggests that
elevated MYC levels are required for the self-renewal and long-
term expansion of cells with features of cancer stem cells.
Reducing MYC activity may be sufficient to achieve cancer inhi-
bition without triggering the side effects that may be observed
with more aggressive therapeutic interventions. However, the
mechanisms bywhichMYCmay control the self-renewal of adult
stem cells and cancer stem cells are still largely unclear; in
particular, whether these mechanisms overlap with the mecha-
nism by which MYC promotes cell growth and proliferation is
not known (Wilson et al., 2004). We also do not know the mech-
anism by which Mycl1 transcription becomes elevated in TPCs
compared to non-TPCs. Inmouse neural cells, Ascl1 can directly
bind to the Mycl1 promoter region (analysis not shown of data
fromWebb et al., 2013) andmay control its expression. It is likely
that a network of transcription factors controls the fate of SCLC
TPCs, including MYC and ASCL1, and this network could
be affected by JQ1 treatment (Augustyn et al., 2014; Lenhart
et al., 2015).
Our ability to successfully identify highly tumorigenic cancer
cells in genetic and patient-derived mouse models, along with
subsequent identification and targeting of transcription factors
that regulate their growth, self-renewal, and survival, couldCell Reports 16, 644–656, July 19, 2016 653
lead to more effective therapies based on the ability to eliminate
TPCs rather than the bulk population of non-tumorigenic cancer
cells.EXPERIMENTAL PROCEDURES
Ethics Statement
Mice were maintained according to practices prescribed by the NIH at Stan-
ford’s Research Animal Facility accredited by the AAPLAC (protocol 13565);
mice were maintained at the Stanford Research Animal Facility accredited
by the Association for Assessment and Accreditation of Laboratory Animal
Care. Similarly, all procedures were carried out in accordance with Home
Office Regulations (UK) and the UK Coordinating Committee on Cancer
Research guidelines and by approved protocols (Home Office Project license
no. 40-3306 and Cancer Research UK Manchester Institute Animal Welfare
and Ethical Review Advisory Board).Human Material and Mouse Tumors
PDX and CDXmodels were generated from extensive stage SCLC patients af-
ter ethical approval and patient consent as previously described (Anderson
et al., 2015; Hodgkinson et al., 2014). Rb/p53/p130 TKO mice that model hu-
man SCLC have been described extensively (Gazdar et al., 2015; Jahchan
et al., 2013; Park et al., 2011; Schaffer et al., 2010). For transplantation assays
and analyses, SCLC tumors from TKO mice around 6–7 months of age were
pooled, chopped, and then digested in 6 ml of PBS containing 120 ml of
100 mg/ml collagenase/dispase (Roche). Tumors were allowed to digest in a
37C shaker for 45 min, followed by cooling on ice before addition of 15 ml
of 1 mg/ml DNase (Sigma) for 5 min. Digested tissue was then passed through
a 100 mm filter and then a 40 mm filter, and red blood cells were lysed in 1 ml
of lysing solution (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), to obtain
a single-cell suspension, which was counted and then stained with FACS
antibodies. NSG immunocompromised mice were used for transplantation
studies of allografts, and tumor cells weremixed withMatrigel (1:1) (BD Biosci-
ences) before subcutaneous injection. For more details on the use of these
models, including isolation and transplantation of single-cell suspensions, as
well as drug treatments, see the Supplemental Experimental Procedures.Cell Culture
Growth conditions for mouse and human cell lines were previously described
(Jahchan et al., 2013; Park et al., 2011; Schaffer et al., 2010). For more details
on the various assays used in this study, see the Supplemental Experimental
Procedures.RNA and Protein Analyses
Protocols for immunoblotting and immunostaining, as well as the analysis of
RNA expression, were described previously (George et al., 2015; Jahchan
et al., 2010). Formore details, see the Supplemental Experimental Procedures.Image Analysis and Statistics
Statistical significance was assayed by Student’s t test with GraphPad Prism
software (two-tailed unpaired and paired t test depending on the experiment).
*p value < 0.05; **p value < 0.01; ***p value < 0.005; NS, not significant. Data
are represented as mean ± SEM. For survival curve analysis and comparison,
the Mantel-Cox test was used. For limiting dilution analyses, extreme limiting
dilution analysis (ELDA) software (Hu and Smyth, 2009), which uses the fre-
quency of tumor-positive and tumor-negative injections at each transplant
dose, was used to determine the stem cell frequency or tumor formation fre-
quency of different groups by entering the numbers of successful outgrowths
and numbers of total injections for each dilution (http://bioinf.wehi.edu.au/
software/elda/). Expected frequencies are reported, as well as the 95%
confidence intervals (lower and upper values are indicated). The p values
comparing groups were calculated by the ELDA software (see http://www.
statsci.org/smyth/pubs/ELDAPreprint.pdf for more information on how
p values were calculated).654 Cell Reports 16, 644–656, July 19, 2016ACCESSION NUMBER
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